Page last updated: 2024-12-05

thioproperazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

thioproperazine: was heading 1963-94; use PHENOTHIAZINES to search THIOPROPERAZINE 1966-94 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

thioproperazine : A phenothiazine derivative in which the phenothiazine tricycle has a dimethylaminosulfonyl substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at N-10. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9429
CHEMBL ID609109
CHEBI ID59120
SCHEMBL ID49902
MeSH IDM0225304

Synonyms (73)

Synonym
tioproferazina
chebi:59120 ,
tioproperazina
BRD-K08619574-334-03-9
10h-phenothiazine-2-sulfonamide, n,n-dimethyl-10-[3-(4-methyl-1-piperazinyl)propyl]-
thioproperazine
PDSP1_000526
PRESTWICK3_000149
316-81-4
n,n-dimethyl-10-[3-(4-methylpiperazin-1-yl)propyl]-10h-phenothiazine-2-sulfonamide
BSPBIO_000258
majeptyl
tioproperazin
rp 7843
tioproferazina [inn-spanish]
skf 5883
megeptil
vontil
mazeptyl
phenothiazine-2-sulfonamide, n,n-dimethyl-10-(3-(4-methyl-1-piperazinyl)propyl)-
tioproperazina [dcit]
sulfenazin
cephalmin
thioproperazinum [inn-latin]
10h-phenothiazine-2-sulfonamide, n,n-dimethyl-10-(3-(4-methyl-1-piperazinyl)propyl)-
einecs 206-262-4
PDSP2_000524
NCGC00179625-01
BPBIO1_000284
PRESTWICK2_000149
n,n-dimethyl-10-[3-(4-methyl-1-piperazinyl)propyl]-10h-phenothiazine-2-sulfonamide
n,n-dimethyl-10-[3-(4-methyl-1-piperazinyl)propyl]phenothiazine-2-sulfonamide
(thioproperazine)-2-dimethylsulfamido-(10-(3-1-methylpiperazinyl-4)propyl)-phenothiazine
thioproperazin
DB01622
thioperazine
2-dimethylsulfamido-(10-(3-1-methylpiperazinyl-4)propyl)-phenothiazine
SPBIO_002197
PRESTWICK1_000149
PRESTWICK0_000149
n,n-dimethyl-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine-2-sulfonamide
L000962
thioproperazine (inn)
D08585
FT-0656305
CHEMBL609109
nsc_92178
cas_316-81-4
bdbm81793
10h-phenothiazine-2-sulfonamide,n,n-dimethyl-10-[3-(4-methyl-1-piperazinyl)propyl]-
A820955
mazeptil
thiproperazine
7843 r.p.
thioproperazine [inn]
unii-yj050aq56x
yj050aq56x ,
thioproperazine [inn:ban]
AKOS015895993
thioproperazine [who-dd]
thioproperazine [mi]
SCHEMBL49902
n,n-dimethyl-10-[3-(4-methyl-1-piperazinyl)propyl]-10h-phenothiazine-2-sulfonamide #
phenothiazine-2-sulfonamide, n,n-dimethyl-10-[3-(4-methyl-1-piperazinyl)propyl]-
VZYCZNZBPPHOFY-UHFFFAOYSA-N
DTXSID1023655
DS-3246
n,n-dimethyl-10-(3-(4-methylpiperazin-1-yl)propyl)-10h-phenothiazine-2-sulfonamide
mfcd00867741
Q2622839
rp 7843; skf 5883; sulfenazin; thioperazine
CS-0017476
HY-A0151

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
phenothiazine antipsychotic drugnull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
phenothiazines
N-alkylpiperazine
N-methylpiperazine
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1480298Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors.
AID345022Binding affinity to human telomerase P2b RNA by STD NMR2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Discovery of ligands for a novel target, the human telomerase RNA, based on flexible-target virtual screening and NMR.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (97)

TimeframeStudies, This Drug (%)All Drugs %
pre-199094 (96.91)18.7374
1990's0 (0.00)18.2507
2000's1 (1.03)29.6817
2010's2 (2.06)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.61 (24.57)
Research Supply Index4.77 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.85%)6.00%
Case Studies1 (0.85%)4.05%
Observational0 (0.00%)0.25%
Other115 (98.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]